Kyowa Kirin buys into Kura leukemia treatment rights for $330M+
Japanese drugmaker Kyowa Kirin is acquiring most of the commercial rights for Kura Oncology’s targeted leukemia treatment, paying $330 million upfront and almost $1.2 billion in possible milestones....
View ArticleAmgen names geneticist and biotech founder to CSO post
Amgen is joining the chorus of large pharmas naming new science leaders. The company said Wednesday that Stanford physician-scientist Howard Chang will be its new chief scientific officer and senior...
View ArticleNovartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on M&A
Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed to Endpoints News on Thursday. And...
View ArticleAizen debuts with AI-driven 'mirror peptide' platform
Aizen Therapeutics has left stealth with $13 million in seed funding and a mission to advance “mirror peptide” drug candidates, with an initial focus on solid tumors and neuroscience. The San...
View ArticleFDA vaccine chief Peter Marks pledges to stay as long as he's welcome
LONDON — The FDA's top leader of vaccines and biologics said Thursday he is not planning to leave his role in light of the incoming Trump administration and the potential for Robert F. Kennedy Jr ...
View ArticleCidara's $100M PIPE; Pyxis Oncology's stock falls on Phase 1 data
Plus, news about argenx, Forte Biosciences, Verrica, Pep2Tango Therapeutics, Eli Lilly, Laekna, Lineage Cell Therapeutics and OneCell Diagnostics: Cidara Therapeutics nabs $105M: The immunotherapy...
View ArticleSamsung Bio's new $668M client; Sanofi expands a factory in France
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has secured a number of ...
View ArticleTrump and RFK Jr. want to ban pharma ads. History isn't on their side
As the healthcare priorities of President-elect Donald Trump and his HHS pick Robert F. Kennedy Jr. take shape, one idea gaining steam is a ban on direct-to-consumer pharmaceutical advertising. Both...
View ArticleAt Jefferies, all that manufacturers want to talk about is GLP-1s
LONDON — Thousands of delegates flooded into the narrow corridors of the Waldorf Hilton this week to attend the Jefferies London Healthcare Conference. It was so busy that at one point, security had to...
View ArticleJazz wins approval for bispecific in biliary tract cancer
Jazz Pharmaceuticals earned an FDA approval on Wednesday for zanidatamab, the HER2-targeted bispecific antibody it picked up from Zymeworks for $50 million upfront. The drug, to be marketed as Ziihera,...
View ArticleAstraZeneca culls Phase 2 opioid use disorder drug
AstraZeneca ended a Phase 2 trial of an experimental opioid use disorder treatment, the UK pharma confirmed to Endpoints News. The termination was due to “discontinuation of the AZD4041 clinical...
View ArticleFDA adcomm raises risk questions on AstraZeneca’s Andexxa
Members of an FDA advisory committee were not asked to vote Thursday on AstraZeneca’s anticoagulant reversal drug Andexxa, but they did raise several safety and efficacy concerns. Last year,...
View ArticleWith yearslong reorganization behind it, Novartis increases its sales guidance
Novartis’ reorganization is paying off, CEO Vas Narasimhan told investors at an event Thursday in London. The company raised its sales guidance through 2028 and now expects to grow sales at a 6% annual...
View ArticlePatient dies in Neurogene's Rett syndrome study
A female Rett syndrome patient died Wednesday after receiving Neurogene's gene therapy in a clinical trial, the company disclosed in a new regulatory filing, after saying earlier this week that she ...
View ArticleEnveda raises $130M for drugs in I&I, obesity and other areas
Biotech startup Enveda has raised a $130 million Series C, the Colorado company said Thursday morning. Founded and led by early Recursion employee Viswa Colluru, the startup will use the funds ...
View ArticleLilly's board undergoes more changes; Merck strategy chief joins Roger...
→ Eli Lilly has appointed Procter & Gamble CEO Jon Moeller to the board of directors, while Goldman Sachs operating partner Karen Walker will resign from the board on Dec. 31 ...
View ArticleNabla Bio moves closer to AI-created antibodies
Protein-making AI models have fueled the launch of a $1 billion startup and a Nobel Prize win in 2024, but are they ready to actually make drugs? Leaders of some of the largest startups working ...
View ArticleLexicon ends commercial work to focus on R&D
Lexicon Pharmaceuticals is reverting to a clinical development company after facing repeated setbacks at the FDA for its type 1 diabetes and chronic kidney disease drug. The Texas biotech is slashing...
View ArticleHalozyme withdraws €2B Evotec acquisition proposal
Halozyme Therapeutics said Friday that it has pulled its proposal to buy Evotec, a struggling German biotech that Halozyme said was "unwilling to engage" in deal talks. Last week, San Diego ...
View ArticleFrom vaccines to psychedelics, five drugmakers on what could change under a...
President-elect Donald Trump and Robert Kennedy, Jr. — his pick to head up the Department of Health and Human Services — were hot topics at the Jefferies London Healthcare Conference this week as...
View Article